A single treatment addressing both the reproductive and metabolic dimensions
For generations, women living with polyendocrine metabolic ovarian syndrome have been asked to choose between treating their fertility and treating their metabolic health — as though the body's systems could be neatly separated. Researchers at the University of Colorado now offer early evidence that injectable semaglutide may dissolve that false choice, showing signs of restoring ovulation while also addressing the weight and insulin dysfunction that shadow the condition. The findings, emerging sooner than expected from an ongoing clinical trial, are preliminary — but they carry the weight of a long-unmet need.
- Women with PMOS have long faced an impossible trade-off: medications that help with fertility often leave metabolic disease unaddressed, and vice versa.
- Early data from the RESTORE trial surfaced faster than anticipated, compelling researchers to publish before the study concluded — a sign the signal was too meaningful to wait on.
- Participants who lost at least 10 percent of their body weight on semaglutide showed reproductive improvements alongside metabolic gains, suggesting the drug may act on both systems at once.
- The findings are proof-of-concept only — larger, longer trials are still needed to confirm whether these dual benefits hold across a wider population and over time.
- If the results are validated, semaglutide could fundamentally shift clinical thinking, offering a single therapy where fragmented, incomplete solutions once stood.
A research team at the University of Colorado Anschutz has published early results suggesting that injectable semaglutide — already established as a weight-loss medication — may simultaneously restore fertility in women with polyendocrine metabolic ovarian syndrome, the condition formerly known as PCOS.
The findings come from RESTORE, an ongoing clinical trial testing semaglutide in adolescents and adults with PMOS. The condition is a complex one: it disrupts menstrual cycles, elevates testosterone, raises infertility risk, and frequently brings obesity and insulin resistance along with it. Existing treatments like metformin and hormonal contraceptives tend to address only one dimension of the disease, leaving women to manage the rest on their own.
What drew the team to publish now was the speed of the results. Among participants aged 12 to 35 who lost at least 10 percent of their body weight on the medication, reproductive improvements appeared earlier than expected. Lead author Melanie Cree, a pediatric endocrinologist at Children's Hospital Colorado, described the appeal plainly: women with PMOS have long been forced to choose between reproductive and metabolic care, and these early findings suggest that choice may not always be necessary.
The researchers are careful to frame this as a promising signal rather than a definitive answer. Larger, longer-term studies are still needed to confirm whether the benefits endure. But if they do, semaglutide could offer something this population has rarely had — a single treatment that addresses both the reproductive and metabolic burdens of their condition at once.
A team of researchers at the University of Colorado Anschutz has published early findings suggesting that injectable semaglutide—a medication already known for helping people lose weight—may do something unexpected: simultaneously restore fertility in women struggling with polyendocrine metabolic ovarian syndrome, the condition formerly called polycystic ovary syndrome or PCOS.
The work, published in Fertility and Sterility, comes from an ongoing clinical trial called RESTORE, which is testing whether semaglutide can help adolescents and adults with PMOS regain ovulation and improve their reproductive prospects. What makes this finding notable is that it addresses a long-standing frustration in treating the condition. Women with PMOS typically face a difficult choice: they can take medications that help regulate their menstrual cycles and hormone levels, or they can take medications that address the metabolic problems—weight gain, insulin resistance, increased risk of diabetes and heart disease—that so often accompany the disorder. Few treatments do both well.
PMOS is a complex condition. It disrupts the menstrual cycle, elevates testosterone, raises the risk of infertility, and frequently brings obesity and metabolic dysfunction along with it. The existing standard treatments—metformin, hormonal contraceptives—tend to be incomplete solutions. They may help with one aspect of the disease while leaving others unresolved. Melanie Cree, a pediatric endocrinologist at Children's Hospital Colorado and the study's lead author, described the appeal of a dual-action approach: "Women with PMOS frequently face a frustrating choice between treatments that target reproductive symptoms and those that address metabolic health. Our early findings suggest injectable semaglutide may have the potential to improve both, offering a more comprehensive approach to care."
The researchers analyzed data from a subset of trial participants aged 12 to 35 who lost at least 10 percent of their body weight while taking the medication. What surprised them was how quickly reproductive improvements appeared. The benefits emerged sooner than the team had anticipated, prompting them to publish these preliminary results even as the larger RESTORE trial continues enrolling and following participants. Cree emphasized the significance of studying this specific population: "Although GLP-1 medications have transformed obesity treatment, there remains a significant need for rigorous data examining how these therapies affect fertility and reproductive function in this population."
It is important to note that these are early findings from an ongoing study. The researchers themselves acknowledge that larger, longer-term investigations will be necessary to confirm whether the reproductive gains hold up over time and across a broader group of patients. The current publication is framed as a proof-of-concept—a promising signal, not yet a definitive answer. But the signal is encouraging enough that it may reshape how clinicians think about treating women with PMOS who also struggle with weight and metabolic health. If semaglutide's benefits prove durable in larger trials, it could offer women with this condition something they have lacked: a single treatment that addresses both the reproductive and metabolic dimensions of their disease simultaneously.
Notable Quotes
Women with PMOS frequently face a frustrating choice between treatments that target reproductive symptoms and those that address metabolic health. Our early findings suggest injectable semaglutide may have the potential to improve both.— Melanie Cree, MD, PhD, pediatric endocrinologist at Children's Hospital Colorado
Although GLP-1 medications have transformed obesity treatment, there remains a significant need for rigorous data examining how these therapies affect fertility and reproductive function in this population.— Melanie Cree, MD, PhD
The Hearth Conversation Another angle on the story
Why does it matter that semaglutide helps with both fertility and weight loss, rather than just one or the other?
Because women with PMOS have been trapped in a bind. If you treat the hormone imbalance, you don't necessarily address the metabolic damage that comes with it—the obesity, the diabetes risk. If you treat the metabolic side, you may not restore ovulation. It's like having two separate diseases that need two separate medicines. A drug that does both is genuinely different.
The study looked at people who lost 10 percent of their body weight. Is that the threshold where the fertility benefits kick in?
That's what they measured in this early analysis—they looked at the subset who hit that 10 percent mark. But we don't know yet if that's a hard threshold or if smaller weight losses help too. That's the kind of detail larger trials will clarify.
The researchers say the reproductive improvements came earlier than expected. What does that tell us?
It suggests the medication might be doing something beyond just "lose weight, feel better." There may be direct metabolic or hormonal effects on ovulation that aren't purely downstream from weight loss. That's worth investigating more carefully.
How confident should women with PCOS be about trying this right now?
Not very. This is proof-of-concept data from a small subset of an ongoing trial. It's genuinely promising, but it's not yet the kind of evidence that would change standard treatment guidelines. The next phase—larger, longer studies—will determine whether this actually works at scale and whether the benefits stick around.
What's the human stakes here?
Women with PMOS face infertility, weight struggles, and metabolic disease all at once. Many are young—this trial includes teenagers. If semaglutide works, it could mean the difference between having biological children and not, and between managing their health with one medication instead of juggling several.